Top-Rated StocksTop-RatedNASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $29.04 +0.52 (+1.83%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About CG Oncology Stock (NASDAQ:CGON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CG Oncology alerts:Sign Up Key Stats Today's Range$28.14▼$29.4250-Day Range$27.52▼$33.7052-Week Range$25.77▼$48.60Volume20,146 shsAverage Volume560,074 shsMarket Capitalization$2.21 billionP/E RatioN/ADividend YieldN/APrice Target$63.88Consensus RatingBuy Company OverviewCG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Read More… CG Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreCGON MarketRank™: CG Oncology scored higher than 35% of companies evaluated by MarketBeat, and ranked 833rd out of 959 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCG Oncology has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCG Oncology has only been the subject of 3 research reports in the past 90 days.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.21% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in CG Oncology has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.21% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in CG Oncology has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.62 News SentimentCG Oncology has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CG Oncology this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,664,200.00 in company stock.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CGON Stock News HeadlinesCG Oncology, Inc. (CGON) Gets a Buy from Bank of America SecuritiesFebruary 13, 2025 | markets.businessinsider.comCG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62%February 3, 2025 | finance.yahoo.comDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. February 18, 2025 | Crypto 101 Media (Ad)A First Take On CG OncologyJanuary 11, 2025 | seekingalpha.comPfizer study impact on CG Oncology to be minimal, says H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comCG Oncology Amends Key Executive Employment AgreementsJanuary 10, 2025 | tipranks.comCG Oncology initiated with a Buy at TD CowenJanuary 8, 2025 | markets.businessinsider.comCG Oncology, Inc. (CGON) Receives a Buy from TD CowenJanuary 8, 2025 | markets.businessinsider.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $28.68 at the beginning of 2025. Since then, CGON shares have increased by 1.3% and is now trading at $29.0430. View the best growth stocks for 2025 here. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.30 million. CG Oncology had a negative net margin of 10,642.98% and a negative trailing twelve-month return on equity of 18.97%. When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share. Who are CG Oncology's major shareholders? Top institutional investors of CG Oncology include Decheng Capital LLC (8.38%), Vanguard Group Inc. (7.71%), Braidwell LP (4.32%) and Foresite Capital Management VI LLC (2.92%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings11/12/2024Today2/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CUSIPN/A CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$63.88 High Stock Price Target$75.00 Low Stock Price Target$50.00 Potential Upside/Downside+124.0%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,610,000.00 Net Margins-10,642.98% Pretax Margin-10,642.98% Return on Equity-18.97% Return on Assets-15.36% Debt Debt-to-Equity RatioN/A Current Ratio35.32 Quick Ratio35.32 Sales & Book Value Annual Sales$200,000.00 Price / Sales10,843.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-14.70Miscellaneous Outstanding Shares76,040,000Free FloatN/AMarket Cap$2.17 billion OptionableOptionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:CGON) was last updated on 2/18/2025 by MarketBeat.com Staff From Our PartnersTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.